Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has scheduled its fourth quarter and full year 2024 financial results conference call for March 6, 2025, at 4:30 p.m. ET.
The company will present financial results and provide a business update through a live conference call and audio webcast. Participants can access the webcast through the Investor Relations section of Atea's website, and telephone participants must register in advance to receive dial-in details. The webcast recording will be available on the company's website for at least 90 days after the event.
Atea Pharmaceuticals (Nasdaq: AVIR), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie antivirali orali, ha programmato la sua conferenza sui risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 6 marzo 2025, alle 16:30 ET.
L'azienda presenterà i risultati finanziari e fornirà un aggiornamento aziendale attraverso una conferenza telefonica dal vivo e un webcast audio. I partecipanti possono accedere al webcast tramite la sezione Relazioni con gli Investitori del sito web di Atea, e i partecipanti telefonici devono registrarsi in anticipo per ricevere i dettagli di accesso. La registrazione del webcast sarà disponibile sul sito web dell'azienda per almeno 90 giorni dopo l'evento.
Atea Pharmaceuticals (Nasdaq: AVIR), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias antivirales orales, ha programado su conferencia sobre los resultados financieros del cuarto trimestre y del año completo 2024 para el 6 de marzo de 2025, a las 4:30 p.m. ET.
La empresa presentará los resultados financieros y proporcionará una actualización empresarial a través de una conferencia telefónica en vivo y un webcast de audio. Los participantes pueden acceder al webcast a través de la sección de Relaciones con Inversores del sitio web de Atea, y los participantes telefónicos deben registrarse con anticipación para recibir los detalles de acceso. La grabación del webcast estará disponible en el sitio web de la empresa durante al menos 90 días después del evento.
Atea Pharmaceuticals (Nasdaq: AVIR)는 경구 항바이러스 치료제를 개발하는 데 중점을 둔 임상 단계의 생명공학 회사로, 2024년 4분기 및 연간 재무 결과에 대한 컨퍼런스 콜을 2025년 3월 6일 오후 4시 30분 ET로 예정했습니다.
회사는 재무 결과를 발표하고 라이브 컨퍼런스 콜 및 오디오 웹캐스트를 통해 비즈니스 업데이트를 제공합니다. 참가자는 Atea 웹사이트의 투자자 관계 섹션을 통해 웹캐스트에 접근할 수 있으며, 전화 참가자는 사전 등록을 통해 다이얼인 세부 정보를 받아야 합니다. 웹캐스트 녹화는 이벤트 후 최소 90일 동안 회사 웹사이트에서 이용할 수 있습니다.
Atea Pharmaceuticals (Nasdaq: AVIR), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies antivirales orales, a programmé sa conférence sur les résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 6 mars 2025 à 16h30 ET.
L'entreprise présentera les résultats financiers et fournira une mise à jour commerciale via une conférence téléphonique en direct et un webcast audio. Les participants peuvent accéder au webcast via la section Relations Investisseurs du site web d'Atea, et les participants par téléphone doivent s'inscrire à l'avance pour recevoir les détails de connexion. L'enregistrement du webcast sera disponible sur le site de l'entreprise pendant au moins 90 jours après l'événement.
Atea Pharmaceuticals (Nasdaq: AVIR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von oralen antiviralen Therapeutika konzentriert, hat seine Konferenz zu den finanziellen Ergebnissen des vierten Quartals und des gesamten Jahres 2024 für den 6. März 2025 um 16:30 Uhr ET angesetzt.
Das Unternehmen wird die finanziellen Ergebnisse präsentieren und ein Unternehmensupdate über eine Live-Konferenzschaltung und einen Audio-Webcast bereitstellen. Die Teilnehmer können auf den Webcast über den Bereich Investor Relations auf der Website von Atea zugreifen, und telefonische Teilnehmer müssen sich im Voraus registrieren, um die Einwahldaten zu erhalten. Die Aufzeichnung des Webcasts wird mindestens 90 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 6, 2025, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2024, and to provide a business update.
To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archive of the audio webcast will be available on Atea’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Our lead program and current focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the Company’s plans relating to the date and time of the anticipated conference call and audio webcast. When used herein, words including “may,” “will,” “anticipates,” “plans,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption “Risk Factors” in the reports the Company files with the SEC, including annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Tim McCarthy
LifeSci Advisors
Tim@lifesciAdvisors.com
FAQ
When will Atea Pharmaceuticals (AVIR) report Q4 and full year 2024 earnings?
How can investors access AVIR's Q4 2024 earnings call?
How long will AVIR's Q4 2024 earnings call recording be available?
What will be discussed in Atea Pharmaceuticals' (AVIR) March 6 conference call?
